Evidence map›Paper›PMID 35111747›Full record

ArticleFrontiers in cell and developmental biology2021

MicroRNA-409-3p Targeting at ATXN3 Reduces the Apoptosis of Dopamine Neurons Based on the Profile of miRNAs in the Cerebrospinal Fluid of Early Parkinson's Disease.

Xuling Tan, Junjian Hu, Fengyu Ming, Lingling Lv, Weiqian Yan, Xinke Peng, Rongrong Bai, Qile Xiao, Hainan Zhang, Beisha Tang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. The Role of miRNAs in Parkinson's Disease: A Systematic Review.International journal of molecular sciences · 2025
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Xuling TanDepartment of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Junjian HuCenter for Medical Genetics, School of Life Science, Central South University, Changsha, China.
Fengyu MingDepartment of Neurology, The First People's Hospital of Huaihua City, HuaiHua, China.
Lingling LvDepartment of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Weiqian YanDepartment of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Xinke PengDepartment of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Rongrong BaiDepartment of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Qile XiaoDepartment of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Hainan ZhangDepartment of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Beisha TangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Chunyu WangDepartment of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Jieqiong TanCenter for Medical Genetics, School of Life Science, Central South University, Changsha, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CNHuaian First People’s Hospital · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precise recognition of early Parkinson's disease (PD) has always been a challenging task requiring more feasible biomarkers to be integrated to improve diagnostic accuracy. MicroRNAs (miRNAs) of cerebrospinal fluid (CSF) are believed to be potential and promising candidate biomarkers for PD. However, the role of altered miRNAs of CSF play in PD is unclear. Here, we recruited patients with early stages of PD and controls to analyze the expression of miRNA in CSF by the Next Generation Sequencing (NGS). Furthermore, we tested the levels of these miRNA in SH-SY5Y cells treated with MPP

Indexed as

apoptosiscerebrospinal fluid—CSFmicroRNAsmiR-409-3pParkinson's disease

Identifiers

PMID35111747
PMCPMC8803123
OpenAlexW4206109804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.